drugset
drugset / Trial / NCT04196205

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

NCT04196205 ↗

Phase 1/2 Unknown 20 enrolled The First Affiliated Hospital of Nanchang University
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.

Timeline

Start
2019-12-01
Primary completion
2020-08-01
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD19 CAR-T Cell therapy 1e+06 cells/kg —
Subject anti-CD19 CAR-T Cell therapy 2e+06 cells/kg —

Indications

acute lymphoblastic leukemia